Drugs / Human Amniotic Epithelial Stem Cell Injection
Human Amniotic Epithelial Stem Cell Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06164288 | Jan → Dec 2024 | acute graft versus host disease | Shanghai iCELL Biotechnology Co., Ltd | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human Amniotic Epithelial Stem Cell Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06164288 ↗ |
| Modality | Cell therapy | “Human Amniotic Epithelial Stem Cell Injection” NCT06164288 ↗ |
| Route | Intravenous | “Intravenous reinfusion of human amniotic epithelial cell injection” NCT06164288 ↗ |